Who are Nebivolol/valsartan combination's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nebivolol-valsartan-combination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Nebivolol/valsartan combination — Competitive Intelligence Brief

Nebivolol/valsartan combination (Nebivolol/valsartan combination) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor antagonist and beta-blocker combination. Area: Cardiovascular.

phase 3 Angiotensin II receptor antagonist and beta-blocker combination Angiotensin II receptor, beta-adrenergic receptors Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Nebivolol/valsartan combination (Nebivolol/valsartan combination) — State University of New York at Buffalo. Nebivolol/valsartan combination works by blocking the effects of the hormone epinephrine and relaxing blood vessels, while valsartan blocks the action of angiotensin II, a potent vasoconstrictor, to lower blood pressure.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nebivolol/valsartan combination TARGET	Nebivolol/valsartan combination	State University of New York at Buffalo	phase 3	Angiotensin II receptor antagonist and beta-blocker combination	Angiotensin II receptor, beta-adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor antagonist and beta-blocker combination class)

State University of New York at Buffalo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nebivolol/valsartan combination — Competitive Intelligence Brief. https://druglandscape.com/ci/nebivolol-valsartan-combination. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab